Type 1 Diabetes: Other Disorders with Type 1 Phenotype

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 152-159

  Kong, Alice P S ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glutamic acid decarboxylase (GAD65); Human leukocyte antigen (HLA); Islet surface antibodies (ICSA); Non obese diabetic (NOD); The enzyme glutamic acid decarboxylase (GAD); The major histocompatibility complex (MHC); Type 1 diabetes mellitus (T1DM)

Indexed keywords

EID: 84986224369     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch9     Document Type: Chapter

References (93)

1. Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care 1985; 8:114-117.
2. Zimmet PZ, Rowley MJ, Mackay IR, Knowles WJ, Chen QY, Chapman LH, et al. The ethnic distribution of antibodies to glutamic acid decarboxylase:presence and levels in insulin-dependent diabetes mellitus in Europoid and Asian subjects. J Diabet Complications 1993; 7:1-7.
3. Tajiman N, La Porte RE, Hibi I, Kitagawa T, Fujita H, Drash AL. A comparison of the epidemiology of youth-onset insulin-dependent diabetes mellitus between Japan and the United States (Allegheny County, Pennsylvania). Diabetes Care 1985; 8 Suppl 1:17-23.
4. Huen KF, Low LC, Wong GW, Tse WW, Yu AC, Lam YY, et al. Epidemiology of diabetes mellitus in children in Hong Kong: the Hong Kong childhood diabetes register. J Pediatr Endocrinol Metab 2000; 13:297-302.
5. Wong GWK, Leung SSF, Opphenheimer SJ. Epidemiology of IDDM in southern Chinese children in Hong Kong. Diabetes Care 1993; 16:926-928.
6. Ko GTC, Chan JCN, Yeung VTF, Chow CC, Li JKY, Lau MSW, et al. Antibodies to glutamic acid decarboxylase in young Chinese diabetic patients. Ann Clin Biochem 1998; 35:761-767.
7. Thai AC, Mohan V, Khalid BA, Cockram CS, Pan CY, Zimmet P, et al. Islet autoimmunity status in Asians with young-onset diabetes (12-40 years): association with clinical characteristics, beta cell function and cardio-metabolic risk factors. Diabetes Res Clin Pract 2008; 80:224-230.
8. Thai AC, Ng WY, Loke KY, Lee WR, Lui KF, Cheah JS. Anti-GAD antibodies in Chinese patients with youth and adult-onset IDDM and NIDDM. D iabetologia 1997; 4 0:1425-1430.
9. Ng MCY, Lee SC, Ko GTC, Li JKY, So WY, Hashim Y, et al. Familial early onset type 2 diabetes in Chinese: the more significant roles of obesity and genetics than autoimmunity. Diabetes Care 2001; 24:667-671.
10. Ng MCY, Li JKY, So WY, Critchley JAJH, Cockram CS, Bell GI, et al. Nature or nuture: an insightful illustration from a Chinese family with hepatocyte nuclear factor 1-alpha diabetes (MODY3). Diabetologia 2000; 43:816-818.
11. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28:2130-2135.
12. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar RP. Maturity-onset diabetes of youth in black Americans. N Engl J Med 1987; 316:285-291.
13. Chan JC, Yeung VT, Chow CC, Ko GT, Mackay IR, Rowley MJ, et al. Pancreatic beta cell function and antibodies to glutamic acid decarboxylase (anti-GAD) in Chinese patients with clinical diagnosis of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 32:27-34.
14. Tan KCB, Mackay IR, Zimmet PZ, Hawkins BR, Lam KSL. Metabolic and immunologic features of Chinese patients with atypical diabetes mellitus. Diabetes Care 2000; 23:353-338.
15. Li JKY, Chan JCN, Zimmet PZ, Rowley MJ, Mackay IR, Cockram CS. Young Chinese adults with new onset of diabetic ketoacidosis: clinical course, autoimmune status and progression of pancreatic beta cell function. Diabetic Med 2000; 17:295-298.
16. Banerji MA, Chaiken RL, Huey H, Tuomi T, Norin AJ, Mackay IR, et al. GAD antibody negative NIDDM in adult Black subjects withdiabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush Diabetes. Diabetes 1994; 43:741-745.
17. Chan JCN, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J 1993; 69:204-210.
18. Lee SC, Ko GTC, Li JKY, Chow CC, Yeung VTF, Critchley JAJH, et al. Factors predicting the age at diagnosis of type 2 diabetes in Hong Kong Chinese. Diabetes Care 2001; 24:646-649.
19. Chan JCN, Ng MCY. Lessons learned from young onset diabetes in China. Curr Diab Rep 2003; 3:101-107.
20. Moller AM, Dalgaard LT, Pociot F, Nerup J, Hansen T, Pedersen O. Mutations in the hepatocyte nuclear factor-1alpha gene in Caucasian families originally classified as having Type I diabetes. Diabetologia 1998; 41:1528-1531.
21. Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr Opin Lipidol 2009; 20:106-111.
22. Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR, et al. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci USA 1999; 96:2198-2203.
23. Wang C, Hu C, Zhang R, Bao Y, Ma X, Lu J, et al. Common variants of hepatocyte nuclear factor 1 βare associated with type 2 diabetes in a Chinese population. Diabetes 2009; 58:1023-1027.
24. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity onset diabetes of the young. N Engl J Med 2001; 345:971-980.
25. Vaxillaire M, Rouard M, Yamagata K, Oda N, Kaisaki PJ, Boriraj VV, et al. Identification of nine novel mutations in the hepatocyte nuclear factor 1 alpha gene associated with maturity-onset diabetes of the young (MODY3). Hum Mol Genet 1997; 6:583-586.
26. Kaisaki PJ, Menzel S, Lindner T, Oda N, Rjasanowski I, Sahm J, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in MODY and early-onset NIDDM: evidence for a mutational hotspot in exon 4. Diabetes 1997; 46:528-535.
27. Frayling TM, Bulman MP, Appleton M, Hattersley AT, Ellard S. A rapid screening method for hepatocyte nuclear factor 1 alpha frameshift mutations; prevalence in maturity-onset diabetes of the young and late-onset non-insulin dependent diabetes. Hum Genet 1997; 101:351-354.
28. Iwasaki N, Oda N, Ogata M, Hara M, Hinokio Y, Oda Y, et al. Mutations in the hepatocyte nuclear factor-1alpha/MODY3 gene in Japanese subjects with early-and late-onset NIDDM. Diabetes 1997; 46:1504-1508.
29. Xu JY, Chan V, Zhang WY, Wat NM, Lam KS. Mutations in the hepatocyte nuclear factor-1alpha gene in Chinese MODY families: prevalence and functional analysis. Diabetologia 2002; 45 :744-746.
30. Xu JY, Dan QH, Chan V, Wat NM, Tam S, Tiu SC, et al. Genetic and clinical characteristics of maturity-onset diabetes of the young in Chinese patients. Eur J Hum Genet 2005; 13:422-427.
31. Lee ET, Lu M, Bennett PH, Keen H. Vascular disease in younger-onset diabetes: comparison of European, Asian and American Indian cohorts of the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 Suppl 2:S78-S81.
32. Cereghini S, Ott MO, Power S, Maury M. Expression patterns of vHNF1 and HNF1 homeoproteins in early postimplantation embryossuggest distinct and sequential developmental roles. Development 1992; 116:783-797.
33. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med 1998; 15:816-820.
34. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997; 17:384-385.
35. So WY, Ng MC, Horikawa Y, Njolstad PR, Li JK, Ma RC, et al. Genetic variants of hepatocyte nuclear factor-1beta in Chinese young-onset diabetic patients with nephropathy. J Diabet Complications 2003; 17:369-373.
36. Li MZ, Yu DM, Yu P, Liu DM, Wang K, Tang XZ. Mitochondrial gene mutations and type 2 diabetes in Chinese families. Chin Med J (Engl) 2008; 121:682-686.
37. Maassen JA, LM TH, Van Essen E, Heine RJ, Nijpels G, Jahangir Tafrechi RS, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 2004; 53 Suppl 1:S103-S109.
38. van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1992; 1:368-371.
39. Ng MCY, Yeung VTF, Chow CC, Li JKY, Smith PR, Mijovic CH, et al. Mitochondrial DNA A3243G mutation in patients with early or late onset Type 2 diabetes mellitus in Hong Kong Chinese. J Endocrinol 2000; 52:557-564.
40. Ji L, Hou X, Han X. Prevalence and clinical characteristics of mitochondrial tRNA leu(UUR) mt 3243 A →G and ND-1 gene mt 3316 G →A mutations in Chinese patients with type 2 diabetes. Chin Med J (Engl) 2001; 114:1205-1207.
41. Xiang K, Wang Y, Wu S, Lu H, Zheng T, Sun D, et al. Mitochondrial tRNA(Leu(UUR)) gene mutation diabetes mellitus in Chinese. Chin Med J (Engl) 1997; 110:372-378.
42. Weng SW, Liou CW, Lin TK, Wei YH, Lee CF, Eng HL, et al. Association of mitochondrial deoxyribonucleic acid 16189 variant (T →C transition) with metabolic syndrome in Chinese adults. J Clin Endocrinol Metab 2005; 90:5037-5040.
43. Chinnery PF, Elliott HR, Patel S, Lambert C, Keers SM, Durham SE, et al. Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes. Lancet 2005; 366:1650-1651.
44. Liou CW, Lin TK, Huei Weng H, Lee CF, Chen TL, Wei YH, et al. A common mitochondrial DNA variant and increased body mass index as associated factors for development of type 2 diabetes: additive effects of genetic and environmental factors. J Clin Endocrinol Metab 2007; 92:235-239.
45. Park KS, Chan JC, Chuang LM, Suzuki S, Araki E, Nanjo K, et al. A mitochondrial DNA variant at position 16189 is associated with type 2 diabetes mellitus in Asians. Diabetologia 2008; 51:602-608.
46. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368:756-760.
47. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008; 29:303-316.
48. Zhao H, Lai F, Tong P, Zhong D, Yang D, Tomlinson B, et al. Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 2003; 52:2759-2766.
49. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?. Diabetologia 2004; 47:157-169.
50. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9:151-159.
51. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. JOP 2005; 6:287-302.
52. Sakagashira S, Sanke T, Hanabusa T, Shimomura H, Ohagi S, Kumagaye KY, et al. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 1996; 45:1279-1281.
53. Sakagashira S, Hiddinga HJ, Tateishi K, Sanke T, Hanabusa T, Nanjo K, et al. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am J Pathol 2000; 157:2101-2109.
54. Poa NR, Cooper GJ, Edgar PF. Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 2003; 46:574-578.
55. Lee SC, Hashim Y, Li JKY, Ko GTC, Critchley JAJH, Cockram CS, et al. The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: evidence for associations with type 2 diabetes and cholesterol levels. J Endocrinol 2001; 54:541-546.
56. Seino S. S20G mutation of the amylin gene is associated with Type II diabetes in Japanese. Study Group of Comprehensive Analysis of Genetic Factors in Diabetes Mellitus. Diabetologia 2001; 44:906-909.
57. Ma Z, Westermark GT, Sakagashira S, Sanke T, Gustavsson A, Sakamoto H, et al. Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 2001; 8:242-249.
58. Chuang LM, Lee KC, Huang CN, Wu HP, Tai TY, Lin BJ. Role of S20G mutation of amylin gene in insulin secretion, insulin sensitivity, and type II diabetes mellitus in Taiwanese patients. Diabetologia 1998; 41:1250-1251.
59. Yokoi N, Kanamori M, Horikawa Y, Takeda J, Sanke T, Furuta H, et al. Association studies of variants in the genes involved in pancreatic beta-cell function in type 2 diabetes in Japanese subjects. Diabetes 2006; 55:2379-2386.
60. Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996; 45:825-831.
61. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, et al. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997; 46:688-694.
62. Nielsen LB, Ploug KB, Swift P, Orskov C, Jansen-Olesen I, Chiarelli F, et al. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol 2007; 156:663-671.
63. van Tilburg JH, Rozeman LB, van Someren H, Rigters-Aris CA, Freriks JP, Pearson PL, et al. The exon 16-3t variant of the sulphonylurea receptor gene is not a risk factor for Type II diabetes mellitus in the Dutch Breda cohort. Diabetologia 2000; 43:681-682.
64. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001; 18:206-212.
65. van Dam RM, Hoebee B, Seidell JC, Schaap MM, de Bruin TW, Feskens EJ . Common variants in the ATP-sensitive K + channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance:population-based studies and meta-analyses. Diabet Med 2005; 22:590-598.
66. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, et al. Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89:6286-6290.
67. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092-1097.
68. Turner RC, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350:1288-1293.
69. Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes. Diabetes Care 2003; 26:2088-2093.
70. Stenstrom G, Gottsater A, Bakhtadze E, Berger B, Sundkvist G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 2005; 54 Suppl 2:S68-S72.
71. Tuomi T, Zimmet P, Rowley MJ, Min HK, Vichayanrat A, Lee HK, et al. Differing frequency of autoantibodies to glutamic acid decarboxylase among Koreans, Thais, and Australians with diabetes mellitus. Clin Immunol Immunopathol 1995; 74:202-206.
72. Fielding AM, Brophy S, Davies H, Williams R. Latent autoimmune diabetes in adults: increased awareness will aid diagnosis. Ann Clin Biochem 2007; 44:321-323.
73. van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres:their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabet Med 2008; 25:117-125.
74. Kucera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M. Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 2003; 133:139-143.
75. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, et al. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000; 52:565-573.
76. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults-one end of the rainbow. J Clin Endocrinol Metab 2006; 91:1654-1659.
77. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I, et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002; 958:117-13078
78. Juneja R, Palmer JP. Type 1 1/2 diabetes: myth or reality? Autoimmunity 1999; 29:65-83.
79. Palmer JP, Hirsch IB. What ' s in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26:536-538.
80. Aycan Z, Berberoglu M, Adiyaman P, Ergur AT, Ensari A, Evliyaoglu O, et al. Latent autoimmune diabetes mellitus in children (LADC) with autoimmune thyroiditis and celiac disease. J Pediatr Endocrinol Metab 2004; 17:1565-1569.
81. Lohmann T, Nietzschmann U, Kiess W. " Lady-like ": is there a latent autoimmune diabetes in the young?. Diabetes Care 2000; 23:1707-1708.
82. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48:2206-2212.
83. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 ( Suppl 1): S62-S67.
84. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med 1998; 15:539-553.
85. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996; 45:622-626.
86. Stenstrom G, Berger B, Borg H, Fernlund P, Dorman JS, Sundkvist G. HLA-DQ genotypes in classic type 1 diabetes and in latent autoimmune diabetes of the adult. Am J Epidemiol 2002; 156:787-796.
87. Imagawa A, Hanafusa T. Fulminant type 1 diabetes-is it an Asian-oriented disease?. Intern Med 2005; 44:913-914.
88. Cho YM, Kim JT, Ko KS, Koo BK, Yang SW, Park MH, et al. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes. Diabetologia 2007; 50:2276-2279.
89. Mohan V, Jaydip R, Deepa R. Type 2 diabetes in Asian Indian youth. Pediatr Diabetes 2007; 8 Suppl 9:28-34.
90. Yajnik CS, Sahasrabudhe RA, Naik SS, Katrak A, Shelgikar KM, Kanitkar SV, et al. Exocrine pancreatic function (serum immunoreactive trypsin, fecal chymotrypsin, and pancreatic isoamylase) in Indian diabetics. Pancreas 1990; 5:631-638.
91. Yoon KH, Ko SH, Cho JH, Lee JM, Ahn YB, Song KH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88:2300-2308.
92. Zhao HL, Sui Y, Guan J, He L, Lai FM, Zhong DR, et al. Higher islet amyloid load in men than in women with type 2 diabetes mellitus. Pancreas 2008; 37:e68-73.
93. Jackson AE, Cassell PG, North BV, Vijayaraghavan S, Gelding SV, Ramachandran A, et al. Polymorphic variations in the neurogenic differentiation-1, neurogenin-3, and hepatocyte nuclear factor-1alpha genes contribute to glucose intolerance in a South Indian population. Diabetes 2004; 53:2122-2125.